Neurocrine Biosciences | NBIX - Operating Expenses



Neurocrine Biosciences reported $541.9M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
ALKERMES USD 297.68M 4.96M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Cytokinetics USD 178.28M 21.06M Jun/2025
Dynavax Technologies USD 81.01M 10.78M Jun/2025
Exelixis USD 354.68M 13.9M Jul/2025
Gilead Sciences USD 4.35B 80M Jun/2025
Halozyme Therapeutics USD 123.28M 48K Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Prothena USD 56.43M 10.59M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Repligen USD 176.41M 13.82M Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Teva Pharmaceutical Industries USD 3.28B 95M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025